Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Just commented on an article about Coherus's biosim on Seeking Alpha

”This has the potential to put launch out to late 2018 or early 2019 - on track with what Mylan has been forecasting with its pegfilgrastim biosimilar”

That’s very interesting. I read your previous article where you mentioned to expect a decision on Mylan’s drug in October so after the Coherus setback I was looking at Mylans drug being up next to the plate in October. I am looking at all this as a Spectrum Pharma (SPPI) shareholder that has its own unique (eg not biosim) long lasting filgrastim compound with results due around the end of the year for a phase 3 trial with Special Protocol Assessment. Although Spectrum claims because it’s a unique compound with its own advantages (e.g. less dose, testing for superiority as a secondary endpoint, its own J code, the Amgen staff hired by Spectrum marketing the compound) and it won’t be in competition with the Neulasta biosimilars, you still have to take that with a grain of salt. Nevertheless, this horse race is getting more interesting.
13 Jun 2017, 02:03 PM

https://seekingalpha.com/article/4081115-coherus-biosimilar-knockback-gives-amgen-neulasta-life?auth_param=mqj99:1ck04ln:066255ba9aa744b0a9f3e60cefbf018f&uprof=44&dr=1